WCM/EADO 2021 | Novel druggable targets for keratinocyte skin cancer
Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, gives an overview of novel drug targets for the treatment of keratinocyte skin cancer. Dr Ascierto outlines data on the anti-PD-1/PD-L1 monoclonal antibody therapies nivolumab and pembrolizumab for cutaneous squamous cell carcinoma (cSCC). Dr Ascierto discusses the benefits of using a combinatorial approach with EGFR inhibitors, highlighting the I-Tackle trial (NCT03666325) of pembrolizumab plus cetuximab in patients with cSCC. Dr Ascierto also comments on the use of oncolytic viruses for the treatment of skin cancer, such as vusolimogene oderparepvec which is being trialled in combination with cemiplimab for SCC in the CERPASS trial (NCT04050436). This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Disclosures
Paolo Ascierto, MD, has participated in a consultancy or advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Array, Merck Serono, Pierre-Fabre, Incyte, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore and Seagen; has received research funding from Bristol Myers Squibb, Roche-Genentech, Array and Sanofi; and has received travel support from MSD.
